|
1
|
Dalgleish AG and O'Byrne KJ: Chronic
immune activation and inflammation in the pathogenesis of AIDS and
cancer. Adv Cancer Res. 84:231–276. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shibata M, Nezu T, Kanou H, Abe H,
Takekawa M and Fukuzawa M: Decreased production of interleukin-12
and type 2 immune responses are marked in cachectic patients with
colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pagès F, Berger A, Camus M, Sanchez-Cabo
F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte
D, et al: Effector memory T cells, early metastasis, and survival
in colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tachibana T, Onodera H, Tsuruyama T, Mori
A, Nagayama S, Hiai H and Imamura M: Increased intratumor
Valpha24-positive natural killer T cells: A prognostic factor for
primary colorectal carcinomas. Clin Cancer Res. 11:7322–7327. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng
C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, et al: Cytokine
profile and prognostic significance of high neutrophil-lymphocyte
ratio in colorectal cancer. Br J Cancer. 112:1088–1097. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ling L, Zhao P, Yan G, Chen M, Zhang T,
Wang L and Jiang Y: The frequency of Th17 and Th22 cells in
patients with colorectal cancer at pre-operation and
post-operation. Immunol Invest. 44:56–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pawa N, Arulampalam T and Norton JD:
Screening for colorectal cancer: Established and emerging
modalities. Nat Rev Gastroenterol Hepatol. 8:711–722. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murdoch C, Muthana M, Coffelt SB and Lewis
CE: The role of myeloid cells in the promotion of tumour
angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi C and Pamer EG: Monocyte recruitment
during infection and inflammation. Nat Rev Immunol. 11:762–774.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Diederichsen AC, Hjelmborg Jv, Christensen
PB, Zeuthen J and Fenger C: Prognostic value of the CD4+/CD8+ ratio
of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR
expression on tumour cells. Cancer Immunol Immunother. 52:423–428.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hua W, Yuan A, Zheng W, Li C, Cui J, Pang
Z, Zhang L, Li Z, Goll R and Cui G: Accumulation of FoxP3+ T
regulatory cells in the tumor microenvironment of human colorectal
adenomas. Pathol Res Pract. 212:106–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh PP, Sharma PK, Krishnan G and
Lockhart AC: Immune checkpoints and immunotherapy for colorectal
cancer. Gastroenterol Rep(Oxf). 3:289–297. 2015.PubMed/NCBI
|
|
13
|
Xu B, Yuan L, Gao Q, Yuan P, Zhao P, Yuan
H, Fan H, Li T, Qin P, Han L, et al: Circulating and
tumor-infiltrating Tim-3 in patients with colorectal cancer.
Oncotarget. 6:20592–21603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuchroo VK, Dardalhon V, Xiao S and
Anderson AC: New roles for TIM family members in immune regulation.
Nat Rev Immunol. 8:577–580. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kong Y, Zhang J, Claxton DF, Ehmann WC,
Rybka WB, Zhu L, Zeng H, Schell TD and Zheng H: PD-1(hi)TIM-3(+) T
cells associate with and predict leukemia relapse in AML patients
post allogeneic stem cell transplantation. Blood Cancer J.
5:e3302015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai C, Xu YF, Wu ZJ, Dong Q, Li MY, Olson
JC, Rabinowitz YM, Wang LH and Sun Y: Tim-3 expression represents
dysfunctional tumor infiltrating T cells in renal cell carcinoma.
World J Urol. 34:561–567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
da Silva IP, Gallois A, Jimenez-Baranda S,
Khan S, Anderson AC, Kuchroo VK, Osman I and Bhardwaj N: Reversal
of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
Cancer Immunol Res. 2:410–422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C,
He J, Wu G, Liu X and Zhang Y: Increased Tim-3 expression in
peripheral NK cells predicts a poorer prognosis and Tim-3 blockade
improves NK cell-mediated cytotoxicity in human lung
adenocarcinoma. Int Immunopharmacol. 29:635–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB, Byrd SR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th.
Springer-Verlag; New York, NY: pp. 143–164. 2010
|
|
20
|
Golden-Mason L, Hurtado CE Waasdorp, Cheng
L and Rosen HR: Hepatitis C viral infection is associated with
activated cytolytic natural killer cells expressing high levels of
T cell immunoglobulin- and mucin-domain-containing molecule-3. Clin
Immunol. 158:114–125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anderson AC: Tim-3, a negative regulator
of anti-tumor immunity. Curr Opin Immunol. 24:213–216. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Imai K, Matsuyama S, Miyake S, Suga K and
Nakachi K: Natural cytotoxic activity of peripheral-blood
lymphocytes and cancer incidence: An 11-year follow-up study of a
general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koda K, Saito N, Oda K, Seike K, Kondo E,
Ishizuka M, Takiguchi N and Miyazaki M: Natural killer cell
activity and distant metastasis in rectal cancers treated
surgically with and without neoadjuvant chemoradiotherapy. J Am
Coll Surg. 197:254–260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kondo E, Koda K, Takiguchi N, Oda K, Seike
K, Ishizuka M and Miyazaki M: Preoperative natural killer cell
activity as a prognostic factor for distant metastasis following
surgery for colon cancer. Dig Surg. 20:445–451. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vivier E, Ugolini S, Blaise D, Chabannon C
and Brossay L: Targeting natural killer cells and natural killer T
cells in cancer. Nat Rev Immunol. 12:239–252. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ndhlovu LC, Lopez-Vergès S, Barbour JD,
Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF and
Lanier LL: Tim-3 marks human natural killer cell maturation and
suppresses cell-mediated cytotoxicity. Blood. 119:3734–3743. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gleason MK, Lenvik TR, McCullar V, Felices
M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ,
Panoskaltsis-Mortari A, et al: Tim-3 is an inducible human natural
killer cell receptor that enhances interferon gamma production in
response to galectin-9. Blood. 119:3064–3072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Halama N, Braun M, Kahlert C, Spille A,
Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I, et al:
Natural killer cells are scarce in colorectal carcinoma tissue
despite high levels of chemokines and cytokines. Clin Cancer Res.
17:678–689. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu LY, Chen DD, He JY, Lu CC, Liu XG, Le
HB, Wang CY and Zhang YK: Tim-3 expression by peripheral natural
killer cells and natural killer T cells increases in patients with
lung cancer-reduction after surgical resection. Asian Pac J Cancer
Prev. 15:9945–9948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jost S, Moreno-Nieves UY, Garcia-Beltran
WF, Rands K, Reardon J, Toth I, Piechocka-Trocha A, Altfeld M and
Addo MM: Dysregulated Tim-3 expression on natural killer cells is
associated with increased Galectin-9 levels in HIV-1 infection.
Retrovirology. 10:742013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang YR, Yan JX and Wang LN: The
diagnostic value of serum carcino-embryonic antigen, alpha
fetoprotein and carbohydrate antigen 19-9 for colorectal cancer. J
Cancer Res Ther. 10 Suppl:S307–S309. 2014. View Article : Google Scholar
|
|
32
|
Zhu Z, Chen Z, Chen C, Yang Z, Xuan W, Hou
Y, Zuo Y and Ren S: Opposite variation tendencies of serum CA724
levels in patients with colon and rectal carcinoma. Mol Clin Oncol.
2:139–145. 2014.PubMed/NCBI
|
|
33
|
Haddad AQ and Margulis V: Tumour and
patient factors in renal cell carcinoma-towards personalized
therapy. Nat Rev Urol. 12:253–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakuishi K, Apetoh L, Sullivan JM, Blazar
BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways
to reverse T cell exhaustion and restore anti-tumor immunity. J Exp
Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
|
